Using bisphosphonates to treat PCa-related bone events

Prostate cancer is the most prevalent non-cutaneous cancer diagnosed in men today, still accounting for a significant amount of morbidity and mortality in spite of increased screening efforts and advances in treatment.

Related Videos

Related Content

Advertisement

October 28th 2024

Vaginal estrogen for GSM not associated with major adverse cardiovascular events

Hannah Clarke

“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

September 6th 2024

Collaboration to advance market launch of ProVate device for pelvic organ prolapse

Hannah Clarke

The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.

March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

March 25th 2024

National Urogynecology Research Agenda: A Path Forward for Advancing the Treatment and Management of Pelvic Floor Disorders

American Urogynecologic Society

Developed by the AUGS Scientific Committee and Research Agenda Writing Group

February 27th 2024

FDA approves cefepime/enmetazobactam for complicated UTI

Hannah Clarke

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.

Related Content

Advertisement

October 28th 2024

Vaginal estrogen for GSM not associated with major adverse cardiovascular events

Hannah Clarke

“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

September 6th 2024

Collaboration to advance market launch of ProVate device for pelvic organ prolapse

Hannah Clarke

The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.

March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

March 25th 2024

National Urogynecology Research Agenda: A Path Forward for Advancing the Treatment and Management of Pelvic Floor Disorders

American Urogynecologic Society

Developed by the AUGS Scientific Committee and Research Agenda Writing Group

February 27th 2024

FDA approves cefepime/enmetazobactam for complicated UTI

Hannah Clarke

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.